Best Biotech Stocks Right Now
AbbVie (NYSE:ABBV)AbbVie is a drug company with a strong exposure to immunology and oncology. The company’s top drug, Humira, represents close to half of the company’s current profits. The company was spun off from Abbott in early 2013.
- ▪AbbVie (NYSE:ABBV)AbbVie is a drug company with a strong exposure to immunology and oncology.
- ▪The company’s top drug, Humira, represents close to half of the company’s current profits.
- ▪The company was spun off from Abbott in early 2013.
2 outlets in our directory ran this story, first to last over 18 hours. All of the coverage we found sits in one bucket: centre. That one-sidedness is itself worth noticing.
- ▪ This REIT Is Today’s Best S&P 500 Stock — Yahoo Finance
Benzinga files mainly under news. We currently carry 10 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Benzinga |
| Canonical URL | https://www.benzinga.com/money/best-biotech-stocks |
| Publication time | Sat, 25 Jul 2026 11:12:25 +0000 |
| Retrieval time | 2026-07-25T11:48:20.558Z |
| Last seen | 2026-07-25T11:48:20.558Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | 6ESTQ9ZCvEXG · 5 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
AbbVie (NYSE:ABBV)AbbVie is a drug company with a strong exposure to immunology and oncology. The company’s top drug, Humira, represents close to half of the company’s current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women’s health. AbbVie(NYSE:ABBV)$259.362.44[0.95%]Quote.Price.last-update: 7:49 PM (Delayed 15-Minutes)Get Real Time HereOpen258.540Close259.360Vol / Avg.4.195M / 6.994MMkt Cap456.429BDay Range256.765 - 260.22052 Wk Range186.770 - 261.635Trade with PublicSellCompare BrokersStart Your Free 14-Day Benzinga Pro TrialImmix Biopharma (NASDAQ:IMMX)Immix Biopharma Inc is a clinical-stage biopharmaceutical company developing Tissue-Specific Therapeutics in oncology and inflammation.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Benzinga.
